Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 4OTHER 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Recurrence 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Camurati-Engelmann Syndrome 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × ascrinvacumab × Clear all
NCT01620970 2021-05-14

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed
14 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Recurrence

NCT02116894 2019-03-14

REGAL-1

Duke University

Phase 1 Completed
11 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡